NHS AYRSHIRE & ARRAN

PATIENT GROUP DIRECTION

Name of Medicine :	Azithromycin 250mg tablets/capsules
Legal Classification :	Prescription Only Medicine
PGD Ref No :	CP 21 011
Replacing PGD Ref No :	CP 19 011

Effective Date :	23 April 2021
Review Date :	22 April 2023

Professional Group authorised to use PGD on completion and submission of an Approved Practitioner Form:	Community Pharmacists registered with GPhC and working in Ayrshire & Arran

PGD prepared/reviewed* by : (*delete as appropriate)			
	Doctor	**Pharmacist**	**Other**
Name	**Ruth Holman**	**Joyce Mitchell**	**Joyce Mitchell**
Signature			
Date	**19/03/2021**	**16/03/2021**	

Approved on behalf of NHS Ayrshire & Arran
Chair or vice chair PGD group:
Name: Allan Thomas
Signature: 
Date: 30/04/2021

Description of Treatment	
Name of medicine : Azithromycin 250mg tablets/capsules	
POM/P/GSL :	Prescription Only Medicine
Pharmaceutical Form :	Tablets/Capsules
Strength :	250mg
Clinical situation for use of this PGD	This PGD covers the supply of azithromycin for use in the treatment of uncomplicated Chlamydia Trachomatis presenting to a community pharmacist when first line treatment with doxycycline is contraindicated.
Inclusion criteria	Individuals for whom doxycycline is contraindicated and are : • Male or female individual aged 13 years or over with a laboratory confirmed positive uncomplicated genital Chlamydia diagnosis. • Male or female individual aged 13 or over who is a sexual contact of any individual in the above group. • Individuals who have recently received treatment for Chlamydia who report having unprotected sexual intercourse with an untreated partner. • Individual gives their consent to providing the relevant clinical information to the pharmacist after the pharmacist has assessed their capacity to consent
Exclusion criteria	• Individuals aged 12 years or under. The Child Protection Team must be contacted for children of 12 years and under who present having had sexual intercourse. • Individuals who the pharmacist has assessed as not being competent to consent. • Where there is no valid consent. • When consent to provide relevant clinical information is refused. • Individuals who are/may be pregnant. • Individuals who are breastfeeding. • Individuals weighing less than 45kg (7st 1lb). Where a individual does not know their weight or scales are not available and the individual may be underweight they should be excluded. • Individuals with known hepatic impairment. • Individuals with known renal impairment. • Individuals with known heart arrhythmia.

	• Individuals presenting with complicated chlamydia infection : ➢ Presence of testicular pain or swelling ➢ Presence of concomitant conjunctivitis ➢ Presence of urinary symptoms ➢ Presence of penile discharge in men or vaginal discharge in women ➢ Presence of pelvic inflammatory disease – abdominal/ pelvic pain, irregular bleeding, deep dyspareunia ➢ Presence of ano-rectal symptoms – rectal discharge, bleeding, pain. • Individuals allergic to macrolide antibiotics such as azithromycin, erythromycin and clarithromycin. • Individuals with known hypersensitivity to any of the excipients of azithromycin. • Individuals with known myasthenia gravis and systemic lupus erythematosus. • Individuals on medicines which interact with azithromycin (see current British National formulary or Summary of product characteristics (SPC) for full list) such as : ➢ Ciclosporin ➢ Digoxin ➢ Ergot Derivatives ➢ Theophylline ➢ Reboxetine
Dosage :	1g (4x250mg tablets/capsules) as a single dose (ideally this dose should be supervised on the day, however individuals can be supplied with the azithromycin to take at a later time) followed by 500mg (2x250mg) tablets/ capsules) for two days. Azithromycin capsules must be taken on an empty stomach i.e. One hour before food or two hours after food however Azithromycin tablets do not need to be taken on an empty stomach.
Total Dosage:	2g
Route of Administration :	Oral
Frequency of Administration :	One single dose of 1g followed by 500mg for 2 days.
Duration of Treatment :	Three days treatment
Total Treatment Quantity :	2 g: 8x 250mg tablets/capsules
Action if patient is excluded from treatment under this PGD	Refer to Medical Practitioner/Nurse Independent Prescriber for further assessment. Explain reasons for exclusion and document with clinical records

Interactions	A full list is available in Appendix 1 of the relevant section of the British National Formulary or in the Summary of Product Characteristics (SPC) for the product being used. Antacids : in individuals receiving Azithromycin and antacids, Azithromycin should be taken at least 1 hour before or 2 hours after the antacid
Adverse Effects	A list of all adverse effects is available in the drug monograph of the BNF or SPC
Follow-up treatment	Every individual should be advised to have a repeat test 6-12 months because people with previous Chlamydia have high rates of re-infection. If symptoms do not improve after treatment advise to seek medical help
Written/Verbal Advice to be given to patient	• Azithromycin should be taken at least 1 hour before or 2 hours after food • Indigestion remedies must not be taken within 1 hour before or 2 hours after Azithromycin • If vomiting occurs within 2 hours of taking tablets individuals who re-present should be referred to Medical Practitioner or sexual health clinic for further treatment • Advise individual regarding common side effects such as gastrointestinal upset, skin rash, antibiotic associated colitis, and candidiasis. For frequent side effects, refer to individual leaflet however it should be noted that Azithromycin is well tolerated by most people. For infrequent side effects refer to current BNF • Avoid direct exposure to sunlight, ultraviolet light and sunbeds • Advise individual to abstain from **all sexual contact (including unprotected sex and oral sex) whilst taking treatment and until 7 days after they and their partner(s) have been treated** • Explain that if sexual contact takes place after treatment with untreated partner there is a significant risk of re-infection and further treatment will be required • Chlamydia is a bacteria that can be passed on by having sex. It can be carried with no symptoms. It is cured with these antibiotics. To make sure these work don't have sex for 7 days after you and any partner(s) have been treated or you may get re-infected. If you wish you can take a test in 4 weeks to make sure it has gone. If you have had Chlamydia once you can still get it again in the future. The best way to stay safe from it is to use condoms, and get a

	checkup if you have a new partner. • Further info on www.shayr.com • Individual must be advised to notify any partners and appropriate partner notification documentation should be completed • Individual must be advised to follow local protocols around contact tracing Written information : Individual information leaflet provide with medication. This should be available in a form that can be easily understood by the person. Where English is not easily understood, translations and properly recognized interpreters should be used. Information about sexual health services within Ayrshire & Arran
Record required of Supply/Administration	A copy of the NHS A&A Community Pharmacy Chlamydia/Gonorrhoea Testing and Treatment proforma, signed by the individual, should be retained and an Individual Medication Record (PMR) should be created for the individual, if it does not already exist, and the following information should be recorded in the PMR individual's medication record (PMR): • Name of preparation • Quantity • Directions for use • Date of supply